United States · Multi-sector
International Aids Vaccine Initiative Inc
International AIDS Vaccine Initiative
US non-profit organisation. Based in: United States. Founded 1996. Main sector: multi-sector.
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access. We develop vaccines and antibodies in and for the developing world and seek to accelerate their introduction in low-income countries. IAVI programs and partnerships are grounded in the regions of the world where the disease burden is the greatest, and our approach emphasizes sustainability. Our network of clinical research center partners in Africa and India helps strengthen in-country research capacity and supports the training and education of the next generation of scientists. The global impact of our science includes fundamental contributions to understanding the biology of HIV infection, which IAVI and others are applying toward advancing vaccine science and immunology. IAVI accelerates scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty. Our global reach, including a clinical research network in five countries in sub-Saharan Africa and in India, has allowed us to make fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work played a key role in facilitating the design of promising HIV vaccine candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising approaches for HIV prevention. Our integrated capabilities in vaccine and antibody discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of prevention methods for HIV and other diseases. Through the Product Development Center, we support external researchers with technical and scientific expertise to accelerate the development of their own products.
- Founded
- 1996
- Income 2023
- $129.7M
Accounts
Income Expenditure
Source: IRS Form 990 (ProPublica) — official register
Data table
| Year | Income | Expenditure | Public funds | Staff | Source |
|---|---|---|---|---|---|
| 2023-12-31 | $129.7M | $132.9M | – | – | IRS Form 990 (ProPublica) |
| 2022-12-31 | $146.8M | $131.2M | – | – | IRS Form 990 (ProPublica) |
| 2021-12-31 | $126.4M | $113.2M | – | – | IRS Form 990 (ProPublica) |
| 2020-12-31 | $97.1M | $96.1M | – | – | IRS Form 990 (ProPublica) |
| 2019-12-31 | $88.5M | $87.8M | – | – | IRS Form 990 (ProPublica) |
| 2018-12-31 | $77.2M | $83.4M | – | – | IRS Form 990 (ProPublica) |
| 2017-12-31 | $80.5M | $85.4M | – | – | IRS Form 990 (ProPublica) |
| 2016-12-31 | $65M | $73.9M | – | – | IRS Form 990 (ProPublica) |
| 2015-12-31 | $72.4M | $67.7M | – | – | IRS Form 990 (ProPublica) |
| 2014-12-31 | $52.5M | $60M | – | – | IRS Form 990 (ProPublica) |
| 2013-12-31 | $66.4M | $58.7M | – | – | IRS Form 990 (ProPublica) |
| 2012-12-31 | $61.5M | $69.1M | – | – | IRS Form 990 (ProPublica) |
| 2011-12-31 | $60.6M | $79.1M | – | – | IRS Form 990 (ProPublica) |
Public funds from donor governments
Payments by donor in the last 5 years
| Donor | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| USAID (United States) | €25.4M | €30.4M | €28.7M | €26.4M | €5M |
| Danida (Denmark) | €672,312 | €672,082 | €671,057 | €670,339 | €669,936 |
| FCDO (United Kingdom) | €2.7M | €430,423 | – | – | – |
Payments to the organisation reported by the aid agencies of 17 countries (USAID, FCDO, BMZ, Sida and others) in their own IATI data, converted to euros at the year's average rate. They include funds passed on to local partners. Not all donors name the recipient of their payments, so figures may be incomplete; EU funds are in their own section.
Spending on declared projects (IATI)
Only the projects the organisation publishes on IATI: usually a fraction of its total spending (median 14% in our checks).
Countries with projects published on IATI
Uganda ↗ 1
Number of activities published on IATI that mention the country, added up over all years. Platforms that raise funds for other organisations publish every small project as a separate activity. Each country opens on d-portal the list of this organisation’s projects in that country.
Projects published on IATI (most recent and largest)
| Project | Country | Period | Spending |
|---|---|---|---|
| Sudan virus vaccine development | Uganda | 2025–… ongoing | $1.2M |
Titles are shown as published by the organisation, in their original language. Spending = disbursements and expenditure reported on IATI, in US$.
Official checks
- Public register
- ProPublica (IRS 990) — active registration
- Latest accounts filed
- 2023 (IRS Form 990 (ProPublica))
Facts from public registers and certification bodies, not a judgement on the organisation; the absence of a label is not a negative sign. Methodology
Timeline
- Founded
- Tax-exempt status (IRS)
- First publication on IATI
Identifiers
EU-TR 685996941523-19 · IATI (d-portal) · ProPublica (IRS 990) · Wikidata